# Safety and Efficacy of VDPHL01 in Males and Females With AGA

> **NCT06527365** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Veradermics, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Androgenetic Alopecia
- AGA
- Male Pattern Baldness

## Interventions

- **DRUG:** VDPHL01

## Key facts

- **NCT ID:** NCT06527365
- **Lead sponsor:** Veradermics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-08
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06527365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06527365, "Safety and Efficacy of VDPHL01 in Males and Females With AGA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06527365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*